| 109.78 -0.01 (-0.01%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 130.55 |
1-year : | 152.48 |
| Resists | First : | 111.77 |
Second : | 130.55 |
| Pivot price | 100.95 |
|||
| Supports | First : | 100.06 |
Second : | 92.83 |
| MAs | MA(5) : | 105.84 |
MA(20) : | 100.92 |
| MA(100) : | 95.91 |
MA(250) : | 80.02 |
|
| MACD | MACD : | 1.5 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 83.3  |
D(3) : | 79.6 |
| RSI | RSI(14): 61.5 |
|||
| 52-week | High : | 111.77 | Low : | 49.38 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ PTGX ] has closed below upper band by 5.1%. Bollinger Bands are 88.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 111.94 - 112.5 | 112.5 - 112.97 |
| Low: | 108.3 - 108.89 | 108.89 - 109.38 |
| Close: | 108.91 - 109.84 | 109.84 - 110.61 |
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Thu, 11 Jun 2026
Protagonist Therapeutics (NASDAQ: PTGX) director exercises 9,000 options, sells 9,000 shares under 10b5-1 plan - Stock Titan
Thu, 11 Jun 2026
PTGX Stock Quote Price and Forecast - CNN
Thu, 11 Jun 2026
571,825 Shares in Protagonist Therapeutics, Inc. $PTGX Bought by Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. - MarketBeat
Wed, 10 Jun 2026
[144] Protagonist Therapeutics, Inc SEC Filing - Stock Titan
Wed, 10 Jun 2026
PTGX: Icotyde's strong launch and a robust pipeline drive growth, with Rusfertide approval expected soon - TradingView
Wed, 10 Jun 2026
Protagonist Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 64 (M) |
| Shares Float | 52 (M) |
| Held by Insiders | 0.7 (%) |
| Held by Institutions | 125.2 (%) |
| Shares Short | 7,290 (K) |
| Shares Short P.Month | 8,400 (K) |
| EPS | -1.81 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 10.21 |
| Profit Margin | -154.9 % |
| Operating Margin | -6.5 % |
| Return on Assets (ttm) | -12.4 % |
| Return on Equity (ttm) | -17.1 % |
| Qtrly Rev. Growth | 99 % |
| Gross Profit (p.s.) | 1.15 |
| Sales Per Share | 1.15 |
| EBITDA (p.s.) | -2.2 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -117 (M) |
| Levered Free Cash Flow | -78 (M) |
| PE Ratio | -60.66 |
| PEG Ratio | 0 |
| Price to Book value | 10.75 |
| Price to Sales | 95.32 |
| Price to Cash Flow | -60.53 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|